Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DYADIC INTERNATIONAL, INC.

(DYAI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Dyadic International, Inc.
Dyadic International, Inc. is a global biotechnology company. The Company is focused on developing and licensing the C1 platform for use in human and animal pharmaceutical applications across the world. The Company has developed a method for producing commercial quantities of enzymes and other proteins, which it uses to develop and produce some of its own industrial enzymes, as well as licensing this technology to third parties. This technology is based on the Myceliopthora thermophila fungus, which the Company named C1. The C1 technology is a fungal expression system for gene discovery, development, expression and production of enzymes and other proteins.

Number of employees : 9 people.
Sales per Business
20192020Delta
Industrial Enzymes and Other Proteins1.68100%1.60100% -4.71%
USD in Million
Sales per region
20192020Delta
United States and Netherlands1.68100%1.60100% -4.71%
USD in Million
Managers
Name Title Age Since
Mark A. Emalfarb President, Chief Executive Officer & Director 64 2015
Ping W. Rawson Chief Financial Officer 45 2019
Ronen Tchelet, Dr. Vice President-Research & Business Development 63 2016
Seth J. Herbst, Dr. Independent Director 62 2008
Michael P. Tarnok Chairman 65 2015
Jack L. Kaye Independent Director 76 2015
Barry C. Buckland, Dr. Independent Director 72 2018
Arindam Bose, Dr. Independent Director 67 2016
Patrick K. Lucy Independent Director 52 2021
Matthew S. Jones MD-Business Development & Licensing 43 -
Members of the board
Name Title Age Since
Michael P. Tarnok Chairman 65 2015
Mark A. Emalfarb President, Chief Executive Officer & Director 64 2015
Seth J. Herbst, Dr. Independent Director 62 2008
Jack L. Kaye Independent Director 76 2015
Barry C. Buckland, Dr. Independent Director 72 2018
Arindam Bose, Dr. Independent Director 67 2016
Patrick K. Lucy Independent Director 52 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 40,332,659 19,861,156 49.2% 12,253,502 30.4% 49.2%
Shareholders
NameEquities%
Mark A. Emalfarb 4,334,917 15.4%
Robert S. Levin 3,548,528 12.6%
David M. Knott Partnership 1,074,339 3.83%
The Vanguard Group, Inc. 1,025,724 3.65%
Portolan Capital Management LLC 567,412 2.02%
Marshall Wace LLP 322,075 1.15%
DG Capital Management Trust 310,500 1.11%
Wasatch Advisors, Inc. 291,800 1.04%
Precept Management LLC 290,000 1.03%
Millennium Management LLC 268,447 0.96%
Company contact information
Dyadic International, Inc.
140 Intracoastal Pointe Drive
Suite 404
Jupiter, FL 33477-5094

Phone : +1.561.743.8333
Fax : +1.561.743.8343
Web : http://www.dyadic.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Dyadic International, Inc.
Sector Other Biotechnology & Medical Research
Connections : Dyadic International, Inc.